Skip to main content
Top

Correction: Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma

Published in:

Excerpt

Correction: Molecular Imaging and Biology (2020) 23:186–195
Title
Correction: Preclinical Development of Near-Infrared-Labeled CD38-Targeted Daratumumab for Optical Imaging of CD38 in Multiple Myeloma
Authors
Nicholas Cho
Sooah Ko
Monica Shokeen
Publication date
05-03-2025
Publisher
Springer International Publishing
Published in
Molecular Imaging and Biology / Issue 3/2025
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-025-01984-8

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

1.75 AMA PRA Category 1 Credits

Explore using biomarker testing to interpret results and guide treatment strategies through an interactive patient simulation and unique educational escape rooms.

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Lilly
Learn more TODO (Link opens in a new window)

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Independent Medical Education Grant:
  • Lilly
Learn more TODO (Link opens in a new window)
Image Credits
Alzheimer’s disease in the biomarker era: preparing the multidisciplinary care team/© Springer Healthcare IME, Navigating neuroimaging in Alzheimer’s care: Practical applications and strategies for integration/© Springer Health+ IME